C07D 215/12
With substituted hydrocarbon radicals attached to ring carbon atoms
Official title: with substituted hydrocarbon radicals attached to ring carbon atoms
C07D215/12 (With substituted hydrocarbon radicals attached to ring carbon atoms) appears on 1,419 US grants and 1,245 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,419
- Published applications
- 1,245
- Assignees
- 719
- Inventors
- 4,665
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 12 | 0 |
| 1977 | 9 | 0 |
| 1978 | 7 | 0 |
| 1979 | 2 | 0 |
| 1980 | 5 | 0 |
| 1981 | 4 | 0 |
| 1982 | 6 | 0 |
| 1983 | 4 | 0 |
| 1984 | 7 | 0 |
| 1985 | 9 | 0 |
| 1986 | 12 | 0 |
| 1987 | 11 | 0 |
| 1988 | 20 | 0 |
| 1989 | 16 | 0 |
| 1990 | 30 | 0 |
| 1991 | 25 | 0 |
| 1992 | 41 | 0 |
| 1993 | 43 | 0 |
| 1994 | 38 | 0 |
| 1995 | 34 | 0 |
| 1996 | 31 | 0 |
| 1997 | 37 | 0 |
| 1998 | 41 | 0 |
| 1999 | 24 | 0 |
| 2000 | 33 | 0 |
| 2001 | 32 | 3 |
| 2002 | 42 | 44 |
| 2003 | 42 | 55 |
| 2004 | 30 | 75 |
| 2005 | 29 | 64 |
| 2006 | 37 | 70 |
| 2007 | 32 | 51 |
| 2008 | 40 | 45 |
| 2009 | 38 | 61 |
| 2010 | 25 | 59 |
| 2011 | 51 | 59 |
| 2012 | 38 | 44 |
| 2013 | 55 | 56 |
| 2014 | 50 | 85 |
| 2015 | 53 | 50 |
| 2016 | 35 | 54 |
| 2017 | 56 | 41 |
| 2018 | 32 | 37 |
| 2019 | 38 | 46 |
| 2020 | 25 | 47 |
| 2021 | 43 | 51 |
| 2022 | 23 | 42 |
| 2023 | 20 | 37 |
| 2024 | 21 | 35 |
| 2025 | 21 | 22 |
| 2026 | 10 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- PAI-1 inhibitors and uses thereof15 Sep 2026US 12,735,402 B2The Cleveland Clinic Foundation
- Enantioselective hydrogenation of 4-substituted 1,2-dihydroquinolines in presence of a chiral iridium catalyst and an additive14 Jul 2026US 12,679,808 B2Bayer Aktiengesellschaft
- TEAD inhibitors and uses thereof16 Jun 2026US 12,655,150 B2Cedilla Therapeutics, Inc.
- Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof26 May 2026US 12,637,400 B2Duk San Neolux Co., Ltd.
- Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse26 May 2026US 12,637,410 B2University of Kentucky Research Foundation
- Novel mitofusin inhibitors17 Sep 2026US 2026/0274810 A1Albert Einstein College of Medicine
- Pai-1 inhibitors and uses thereof20 Aug 2026US 2026/0242355 A1The Cleveland Clinic Foundation
- Amide compounds or salts thereof, bactericidal agents for agriculture and horticulture containing said compounds, and method of using same23 Jul 2026US 2026/0206763 A1Nihon Nohyaku Co., Ltd.
- Methods and materials for increasing level of phosphorylated ampk protein21 May 2026US 2026/0138955 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Acetyl-coa carboxylase modulators23 Apr 2026US 2026/0109673 A1Monsanto Technology LLC
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity220US 5,089,509 AAllergan, Inc. · 1992
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997